Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 13Gynecologic 5Plasma cell 3Breast 3Sarcoma 2Other solid neoplasm 2Other hematologic neoplasm 2Myeloid 2Lymphoid 2Gastrointestinal 2Thoracic 1Other 1NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
TIC10 compound × Endocrine × Clear all
NCT03034200 2024-11-26

Phase 2 Study of ONC201 in Neuroendocrine Tumors

Case Comprehensive Cancer Center

Phase 2 Completed
30 enrolled 12 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡